...which has exclusive rights to develop and commercialize CK-101 outside of undisclosed Asian countries from Suzhou NeuPharma Co. Ltd....
...deal. Checkpoint Therapeutics Inc. (NASDAQ:CKPT), New York, N.Y. Fortress Biotech Inc. (NASDAQ:FBIO), New York, N.Y. Suzhou NeuPharma Co. Ltd....
...PFS) Status: Phase I/II data Milestone: Start Phase III (2019) Jennie Walters CK-101, RX518 Checkpoint Therapeutics Inc. Fortress Biotech Inc. Suzhou NeuPharma Co. Ltd. Epidermal...

...glioma. Phoenix Biotechnology Inc. has oleandrin (PBI-05204) in Phase I testing to treat solid tumors. Suzhou NeuPharma Co. Ltd....

...deal. Checkpoint Therapeutics Inc. , New York, N.Y. Fortress Biotech Inc. (NASDAQ:FBIO), New York, N.Y. Suzhou NeuPharma Co. Ltd....

...Suzhou NeuPharma began an open-label, Australian Phase I trial of Rx10 8. Suzhou NeuPharma Co. Ltd. , Suzhou, China...

...undisclosed EGFR mutations. Coronado declined to disclose further details, and NeuPharma could not be reached. Suzhou NeuPharma Co. Ltd....